{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8"],"submitter":["Cho I"],"pubmed_abstract":["<b>Background:</b> Clinical trials of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with chronic heart failure and atrial fibrillation (AF) have demonstrated reduced risks of stroke and bleeding compared with vitamin K antagonists (VKAs). Here, we aim to assess the clinical efficacy and safety of rivaroxaban, a NOAC, compared with warfarin, a VKA, and the effects of rivaroxaban on cardiovascular biomarkers in patients with acute decompensated heart failure (ADHF) with reduced ejection fraction (≤40%) and AF. <b>Methods:</b> Rivaroxaban Once-daily vs. dose-adjusted vitamin K antagonist on biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) is a randomized, open-labeled, controlled, prospective, multicenter pilot study designed to assess ca"],"journal":["Frontiers in cardiovascular medicine"],"pagination":["765081"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8790040"],"repository":["biostudies-literature"],"pubmed_title":["Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study."],"pmcid":["PMC8790040"],"pubmed_authors":["Choi EY","Chung WJ","Cho I","Byun YS","Kim HM","Oh J","Yoo BS","Pyun WB","Chung H","Kang SM","Kim IC","Lee JH"],"additional_accession":[]},"is_claimable":false,"name":"Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study.","description":"<b>Background:</b> Clinical trials of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with chronic heart failure and atrial fibrillation (AF) have demonstrated reduced risks of stroke and bleeding compared with vitamin K antagonists (VKAs). Here, we aim to assess the clinical efficacy and safety of rivaroxaban, a NOAC, compared with warfarin, a VKA, and the effects of rivaroxaban on cardiovascular biomarkers in patients with acute decompensated heart failure (ADHF) with reduced ejection fraction (≤40%) and AF. <b>Methods:</b> Rivaroxaban Once-daily vs. dose-adjusted vitamin K antagonist on biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) is a randomized, open-labeled, controlled, prospective, multicenter pilot study designed to assess ca","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-04T13:43:25.089Z","creation":"2022-02-11T15:37:52.566Z"},"accession":"S-EPMC8790040","cross_references":{"pubmed":["35096995"],"doi":["10.3389/fcvm.2021.765081"]}}